Pfizer Approval
A one-time dose of the Pfizer product, BEQVEZ, has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients.
Pfizer (PFE) announced today that . . .
This content is for paid subscribers.
Today’s Highlights
April 26, 2024